Rilpivirine free base (injectable) API was developed at Minakem’s Canadian facility (Delmar Chemicals Inc.) in 2024. Rilpivirine free base API has CAS Number 500287-72-9
From a regulatory perspective, Minakem offers:
Minakem’s Rilpivirine free base API brings:
Rilpivirine free base API is is approved in combination with cabotegravir for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml).
This combo drug marketed by the originator under the brand name Rekambys. This medication improves significantly the patient wellness as it is a long-acting intramuscular injection to be given once every month or every two months
Minakem Montreal (Delmar chemicals Inc.) has been manufacturing Active Pharmaceutical Ingredients (APIs) since 1941.
It is the largest API facility in Canada, benefiting from a strong scientific and technological environment.
Located close to its U.S. customers in the New Jersey and Boston areas, Montreal also has a strong tradition of serving the entire North American market, as well as Latin America, Europe, Japan, China, and India.
Minakem Montreal collaborates daily with Minakem’s other European facilities, leveraging their complementary expertises in solid engineering, analytics, global regulatory affairs, and other capabilities to enhance competitiveness.
Minakem brings over 40 years of experience in developing, scaling up, registering Drug Master Files (DMFs), and manufacturing complex Active Pharmaceutical Ingredients (APIs), including chiral small molecules, steroids, and highly potent APIs (HPAPIs)—primarily used in oncology treatments.
As supply chain performance becomes increasingly critical to customers’ success, Minakem focuses on delivering:
Rilpivirine free base (injectable) Sterile API’s data are available on
PharmaofferRilpivirine free base (injectable) Sterile API additional data are available on
Wikipedia